
|Videos|October 5, 2016
The Significant Need for New Agents to Treat MDS
Author(s)Marco Davila, MD, PhD
Marco Davila, MD, PhD, medical oncologist, Moffitt Cancer Center, discusses the significant need for new agents to treat MDS.
Advertisement
Advertisement
Advertisement
Advertisement
Trending on Targeted Oncology - Immunotherapy, Biomarkers, and Cancer Pathways
1
Enfortumab Vedotin Plus Pembrolizumab Improves Survival in MIBC
2
FDA Grants Regular Approval to Rucaparib for BRCA-Mutated mCRPC
3
FDA Approves Subcutaneous Amivantamab for EGFR-Mutated NSCLC Indications
4
Illuminating the Sequence of Third-Line Therapies in Metastatic CRC
5








































